Excellent analysis soc040713. CTIX is definitely flying below the radar. Which is a good thing as it gave us early retail buyers the chance to get in at prices that I believe will seem cheap once CTIX uplists and institutional buying starts in earnest.
The little guy and the early investors usually get killed in these early stage bio-techs. Not the case with CTIX!
CTIX is an unusual diamond in the rough. Here we are at an enviable share price and share structure, poised for an ever greater rally to higher share prices. Well funded by Aspire Capital, the Gold Standard of bio-tech financing, with minimal dilution, and with three drugs either in clinical trials or soon to enter.
And yes, CTIX has completed Phase 2b clinical trial for a new class of antibiotics. Phase 3 is coming!
Data suggests Brilacidin may also be the new 'best in class' with a one day dosing vs 7 days for the current best in class. And amazingly, science showing Brilacidin does not succumb to resistance. Boom!
This baby bio-tech is a sleeping giant. Yes a top performer for 2014, but IMO we ain't seen nothing yet.
I pose the question: What will happen when $10 -$30 million wants to buy CTIX shares? That is peanuts for the market.
News 
Market Data 
Discover 
